Saol Therapeutics, GeneDx Partner to ID Patients With Rare Mitochondrial Disease

Jordin Tedesco News

Saol Therapeutics and GeneDx have partnered to identify patients with rare mitochondrial disease. There are currently no FDA-approved treatments for patients with PDCD so this is a huge step in the right direction:

Connect With Confidence.

We guarantee to pour our resources into finding top-notch talent for you, bringing depth, determination and dedication to each and every recruiting project.

Contact Us